Afficher la notice abrégée

dc.contributor.authorBenjamin Gesundheit*
dc.contributor.authorJoshua P. Rosenzweig*
dc.date.accessioned2021-02-11T21:38:40Z
dc.date.available2021-02-11T21:38:40Z
dc.date.issued2017*
dc.date.submitted2018-02-27 16:16:45*
dc.identifier25658*
dc.identifier.issn16648714*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/55224
dc.description.abstractThe ability to genetically engineer oncolytic viruses in order to minimize side effects and improve the selective targeting of tumor cells has opened up novel opportunities for treating cancer. Understanding the mechanisms involved and the complex interaction between the viruses and the immune system will undoubtedly help guide the development of new strategies. Theranostic biomarkers to monitor these therapies in clinical trials serve an important need in this innovative field and demand further research.*
dc.languageEnglish*
dc.relation.ispartofseriesFrontiers Research Topics*
dc.subjectR5-920*
dc.subjectRC581-607*
dc.subjectRC254-282*
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.othertheranostic nanomedicine*
dc.subject.othercancer immunotherapy*
dc.subject.otheroncolytic viruses*
dc.subject.otherantitumor immunity*
dc.subject.otheroncoimmunology*
dc.subject.othergene expression*
dc.subject.othertransgenes*
dc.titleOncolytic Viruses - Genetically Engineering the Future of Cancer Therapy*
dc.typebook
oapen.identifier.doi10.3389/978-2-88945-358-0*
oapen.relation.isPublishedBybf5ce210-e72e-4860-ba9b-c305640ff3ae*
oapen.relation.isbn9782889453580*
oapen.pages193*


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

https://creativecommons.org/licenses/by/4.0/
Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by/4.0/